Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Despite the essential role secretory IgAs play in the defense against pathogenic invasion and the proposed value of recombinant secretory IgAs as novel therapeutics, currently there are no IgA-based therapies in clinics. Secretory IgAs are complex molecules and the major bottleneck limiting their therapeutic potential is a reliable recombinant production system. In this report, we addressed this issue and established a fast and robust production method for secretory IgAs in CHO-K1 cells using BAC-based expression vectors. As a proof of principle, we produced IgAs against Clostridium difficile toxins TcdA and TcdB. Recombinant secretory IgAs produced using our expression system showed comparable titers to IgGs, widely used as therapeutic biologicals. Importantly, secretory IgAs produced using our method were functional and could efficiently neutralize Clostridium difficile toxins TcdA and TcdB. These results show that recombinant secretory IgAs can be efficiently produced, thus opening the possibility to use them as therapeutic agents in clinics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbiotec.2021.02.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein.
Elife
May 2025
Center for Advanced Antibody Drug Development, University of Toyama, Toyama, Japan.
Intranasal vaccination is an attractive strategy for preventing COVID-19 disease as it stimulates the production of multimeric secretory immunoglobulin A (IgA), the predominant antibody isotype in the mucosal immune system, at the target site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, intranasal vaccine efficacy is evaluated based on the measurement of polyclonal antibody titers in nasal lavage fluid. However, how individual multimeric secretory IgA protects the mucosa from SARS-CoV-2 infection remains to be elucidated.
View Article and Find Full Text PDFIdentification of Antigens Recognized by Murine Intestinal IgAs by a Gel-Independent Immunoproteomic Approach.
J Proteome Res
February 2025
Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza de Ramón y Cajal s/n, 28040 Madrid, Spain.
As part of the intestinal microbiota, can elicit a humoral response in the gastrointestinal tract (GIT) that is mainly directed toward hyphal antigens. This response has been implicated in controlling the invasive form of the fungus and maintaining the yeast as an innocuous commensal. However, the specific targets of this response are still unknown.
View Article and Find Full Text PDFSARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses.
EBioMedicine
December 2023
Department of Pathology and Immunology, Centre of Vaccinology, University of Geneva, Geneva, Switzerland. Electronic address:
Background: Mucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory tract, and potentially in limiting virus replication and therefore onward transmission. While systemic immunity to SARS-CoV-2 is well understood, we have a limited understanding about the antibodies present on the nasal mucosal surfaces.
Methods: In this study, we evaluated SARS-CoV-2 mucosal antibodies following previous infection, vaccination, or a combination of both.
α-Glucosidase inhibitors boost gut immunity by inducing IgA responses in Peyer's patches.
Front Immunol
December 2023
Division of Biochemistry, Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
Article Synopsis
- - Peyer's patches (PPs) are important gut tissues that trigger the immune response to substances from both beneficial microbes and pathogens by producing immunoglobulin A (IgA), which helps maintain gut health and fight infections.
- - Antidiabetic drugs known as α-glucosidase inhibitors (α-GIs), like voglibose and acarbose, modify the gut microbiota and have been shown to enhance the immune response by increasing the production of immune cells related to IgA in mice.
- - This study suggests that α-GIs can boost specific IgA responses, particularly against pathogens like Typhimurium, indicating their potential use as an enhancer for mucosal vaccines.
Correlation between salivary immunoglobulin A and interleukin-1beta in smokers with dental caries.
F1000Res
May 2023
Department of Physics, Faculty of Science, University of Kufa, Najaf, Iraq.
. Dental caries is one of the most common infectious diseases of the oral cavity, and is an inflammatory disease caused by several factors. Interleukin-1β (IL-1β) is a major mediator of acute inflammation and essential for the development of specific immune responses.
View Article and Find Full Text PDF